David DonabedianFounder

United States - Boston, Massachusetts

David is a senior executive with over 20 years of professional experience and expertise leading business development, venture teams and demonstrated track record of company creation. Operational expertise leading and launching early-stage organizations (Solu Therapeutics, DEM Bio, ImmuneID, and Axial) and international organizations (AbbVie, GSK, Accenture and Dow). Seasoned relationship builder with expertise in fundraising, forging strategic partnerships, M&A and building world class SABs and management teams in biotech and biopharma. Founding CEO for CNS company Newleos Therapeutics, Co-founder/ CEO for precision medicine Company Solu Therapeutics, Co-founder/ CEO for macrophage cancer company, DEM Bio, Co-founder/ CEO of CNS company Axial Therapeutics and start-up CEO for precision Immunology Company, ImmuneID, and founding executive of a precision CNS Company, Alcyone Therapeutics. Board member of a medical device company, Anuncia. Also, experienced investor with several successful exits.

David holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of DEM Bio, Alcyone Therapeutics and Anuncia Inc.